デフォルト表紙
市場調査レポート
商品コード
1671863

組み換えワクチン市場:タイプ別、適応症別、エンドユーザー別、流通チャネル別、地域別

Recombinant Vaccine Market, By Type, By Indication, By End User, By Distribution Channel, By Geography


出版日
ページ情報
英文 156 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
組み換えワクチン市場:タイプ別、適応症別、エンドユーザー別、流通チャネル別、地域別
出版日: 2025年02月26日
発行: Coherent Market Insights
ページ情報: 英文 156 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

組み換えワクチンの世界市場は、2025年には125億2,000万米ドルと推定され、2032年には271億7,000万米ドルに達すると予測され、2025年から2032年までのCAGRは11.7%で推移すると予測されています。

レポート範囲 レポート詳細
基準年 2024 2025年の市場規模 125億2,000万米ドル
実績データ 2020年から2024年まで 予測期間 2025年から2032年
予測期間:2025年~2032年 CAGR: 11.70% 2032年の価値予測 271億7,000万米ドル
図.組み換えワクチン市場シェア(%)、2025年地域別
Recombinant Vaccine Market-IMG1

組み換えワクチンは、ワクチン抗原をコードする遺伝子を酵母、細菌、ウイルスなどの別の生物の遺伝子と組み合わせることにより、組換えDNA技術を用いて開発されます。組換え遺伝子を宿主細胞に導入し、これを大型発酵槽で培養して抗原タンパク質を生産します。組換え技術は、季節や病気の流行に関係なく、正確に制御された条件下で抗原を大量生産できるため、従来のワクチン生産における多くの制約を克服しています。低生産コスト、高収率、スケーラビリティといった利点から、世界の組み換えワクチン市場は予測期間中に大きな成長が見込まれています。

市場力学:

世界の組み換えワクチン市場は、感染症の流行増加、ワクチン接種に対する意識の高まり、組換えDNA生産技術の技術的進歩などの要因により、堅調な成長が見込まれます。しかし、高い開発コストと厳しい規制の枠組みが市場成長の妨げになると予想されます。一方、未開発の人口を多く抱える新興国には、メーカーにとって有利なビジネスチャンスがあります。市場開発企業は研究開発に投資し、新たな疾患適応のワクチンや、健診時に追加接種の機会を提供し、患者のコンプライアンスを向上させる混合ワクチンを開発しています。

本調査の主な特徴

本レポートでは、世界の組み換えワクチン市場を詳細に分析し、2024年を基準年とした予測期間(2025-2032年)の市場規模と年間平均成長率(CAGR%)を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の組み換えワクチン市場の主要企業をプロファイルしています。

主要企業には、Merck &Co., Inc.、Sanofi S.A.、Pfizer Inc.、GlaxoSmithKline Plc.、Johnson &Johnson、Novavax, Inc.、AstraZeneca Plc.、Dynavax Technologies Corporation、Serum Institute of India Pvt. Ltd.、Emergent BioSolutions Inc.、Bharat Biotech、Protein Sciences Corporation、VBI Vaccines Inc.、Inovio Pharmaceuticals, Inc.などがあります。

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関して、情報に基づいた意思決定を行うことができます。

組み換えワクチンの世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。

利害関係者は、世界の組み換えワクチン市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学、規制、動向分析

  • 市場力学
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • PORTERの分析
  • 合併と買収のシナリオ
  • 業界動向

第4章 世界の組み換えワクチン市場、タイプ別、2020年~2032年

  • 弱毒化組み換えワクチン
  • ベクター組み換えワクチン
  • サブユニット組み換えワクチン

第5章 世界の組み換えワクチン市場、適応症別、2020年~2032年

  • ヒトパピローマウイルス(HPV)
  • 髄膜炎菌
  • B型肝炎
  • インフルエンザ
  • ロタウイルス
  • 帯状疱疹
  • その他

第6章 世界の組み換えワクチン市場、エンドユーザー別、2020年~2032年

  • 小児科
  • 成人
  • 高齢者向け

第7章 世界の組み換えワクチン市場、流通チャネル別、2020年~2032年

  • 病院および薬局
  • 政府サプライヤー
  • ワクチン接種センター

第8章 世界の組み換えワクチン市場、地域別、2020年~2032年

  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第9章 競合情勢

  • Merck & Co., Inc.
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Novavax, Inc.
  • AstraZeneca Plc.
  • Dynavax Technologies Corporation
  • Serum Institute of India Pvt. Ltd.
  • Emergent BioSolutions Inc.
  • Bharat Biotech
  • Protein Sciences Corporation
  • VBI Vaccines Inc.
  • Inovio Pharmaceuticals, Inc.

第10章 アナリストの推奨事項

  • 運命の輪
  • アナリストの見解
  • 一貫した機会マップ

第11章 参考文献と調査手法

  • 参考文献
  • 調査手法
  • 出版社について
目次
Product Code: CMI455

Global Recombinant Vaccine Market is estimated to be valued at US$ 12.52 Bn in 2025 and is expected to reach US$ 27.17 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: US$ 12.52 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 11.70% 2032 Value Projection: US$ 27.17 Bn
Figure. Recombinant Vaccine Market Share (%), By Region 2025
Recombinant Vaccine Market - IMG1

Recombinant vaccines are developed using recombinant DNA technology by combining genes that code for vaccine antigens with the genes of another organism like yeast, bacteria, or viruses. The recombinant genes are then transferred into host cells which are then cultured in large fermenters to produce antigen proteins. Recombinant technology overcomes many limitations of conventional vaccine production as antigens can be mass produced in precisely controlled conditions regardless of season or disease outbreak. With benefits of low production cost, high yield and scalability, the global recombinant vaccine market is expected to experience significant growth over the forecast period.

Market Dynamics:

The global recombinant vaccine market is projected to witness robust growth attributable to factors such as increasing prevalence of infectious diseases, rising awareness about vaccination, and technological advancement in recombinant DNA production techniques. However, high development costs and stringent regulatory framework are expected to impede the market growth. On the other hand, emerging economies with large untapped populations present lucrative opportunities for manufacturers. Market players are investing in R&D to develop vaccines for new disease indications as well as combination vaccines which provide an opportunity for additional vaccination during well-child visits, thereby improving patient compliance.

Key Features of the Study:

This report provides in-depth analysis of the global recombinant vaccine market and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global recombinant vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Merck & Co., Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, Novavax, Inc., AstraZeneca Plc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Emergent BioSolutions Inc., Bharat Biotech, Protein Sciences Corporation, VBI Vaccines Inc., and Inovio Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global recombinant vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant vaccine market

Market Segmentation

  • By Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Attenuated Recombinant Vaccines
    • Vector Recombinant Vaccines
    • Subunit Recombinant Vaccines
  • By Indication Insights (Revenue, USD Bn, 2020 - 2032)
    • Human Papillomavirus (HPV)
    • Meningococcal
    • Hepatitis B
    • Influenza
    • Rotavirus
    • Herpes Zoster
    • Others
  • By End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Pediatric
    • Adult
    • Geriatric
  • By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital & Retail Pharmacies
    • Government Suppliers
    • Vaccination Centers
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Pfizer Inc.
    • GlaxoSmithKline Plc.
    • Johnson & Johnson
    • Novavax, Inc.
    • AstraZeneca Plc.
    • Dynavax Technologies Corporation
    • Serum Institute of India Pvt. Ltd.
    • Emergent BioSolutions Inc.
    • Bharat Biotech
    • Protein Sciences Corporation
    • VBI Vaccines Inc.
    • Inovio Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Recombinant Vaccine Market, By Type
    • Global Recombinant Vaccine Market, By Indication
    • Global Recombinant Vaccine Market, By End User
    • Global Recombinant Vaccine Market, By Distribution Channel
    • Global Recombinant Vaccine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
    • Restraint
    • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Recombinant Vaccine Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Attenuated Recombinant Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Vector Recombinant Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Subunit Recombinant Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Recombinant Vaccine Market, By Indication, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Human Papillomavirus (HPV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Meningococcal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hepatitis B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Influenza
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Rotavirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Herpes Zoster
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Recombinant Vaccine Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Recombinant Vaccine Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital & Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Government Suppliers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Vaccination Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Recombinant Vaccine Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline Plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novavax, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca Plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dynavax Technologies Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Serum Institute of India Pvt. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Emergent BioSolutions Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bharat Biotech
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Protein Sciences Corporation
  • VBI Vaccines Inc.
  • Inovio Pharmaceuticals, Inc.

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us